| Primary |
| Breast Cancer |
15.3% |
| Lymphoma |
10.0% |
| Drug Use For Unknown Indication |
8.1% |
| Non-hodgkin's Lymphoma |
6.9% |
| Acute Lymphocytic Leukaemia |
6.7% |
| Product Used For Unknown Indication |
6.6% |
| Diffuse Large B-cell Lymphoma |
5.3% |
| B-cell Lymphoma |
5.2% |
| Chronic Lymphocytic Leukaemia |
4.8% |
| Burkitt's Lymphoma |
4.3% |
| Acute Myeloid Leukaemia |
3.5% |
| Hodgkin's Disease |
3.5% |
| Adult T-cell Lymphoma/leukaemia |
3.4% |
| Systemic Lupus Erythematosus |
2.8% |
| Prophylaxis |
2.7% |
| Bone Marrow Conditioning Regimen |
2.6% |
| T-cell Lymphoma |
2.3% |
| Multiple Myeloma |
2.1% |
| Mantle Cell Lymphoma |
2.1% |
| Infection Prophylaxis |
1.9% |
|
| Pyrexia |
13.4% |
| Vomiting |
9.3% |
| Treatment Related Secondary Malignancy |
7.3% |
| Acute Myeloid Leukaemia |
6.1% |
| White Blood Cell Count Decreased |
6.1% |
| Respiratory Failure |
5.7% |
| Sensation Of Foreign Body |
5.7% |
| Interstitial Lung Disease |
4.9% |
| Sepsis |
4.9% |
| Pneumonia |
4.5% |
| Thrombocytopenia |
4.5% |
| Tumour Lysis Syndrome |
4.5% |
| Pancytopenia |
3.7% |
| Death |
3.3% |
| Renal Failure |
3.3% |
| Neutropenic Infection |
2.8% |
| Pulmonary Embolism |
2.8% |
| Stomatitis |
2.8% |
| Venoocclusive Liver Disease |
2.4% |
| Hepatitis |
2.0% |
|
| Secondary |
| Breast Cancer |
17.3% |
| Product Used For Unknown Indication |
12.3% |
| Drug Use For Unknown Indication |
9.4% |
| B-cell Lymphoma |
8.7% |
| Non-hodgkin's Lymphoma |
5.7% |
| Lymphoma |
5.6% |
| Chronic Lymphocytic Leukaemia |
5.6% |
| Diffuse Large B-cell Lymphoma |
5.6% |
| Prophylaxis |
5.1% |
| Acute Lymphocytic Leukaemia |
5.0% |
| Bone Marrow Conditioning Regimen |
2.9% |
| Premedication |
2.2% |
| Burkitt's Lymphoma |
2.2% |
| Acute Myeloid Leukaemia |
2.2% |
| Adult T-cell Lymphoma/leukaemia |
1.9% |
| Plasma Cell Myeloma |
1.8% |
| Multiple Myeloma |
1.7% |
| Prophylaxis Of Nausea And Vomiting |
1.7% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iv |
1.6% |
| Stem Cell Transplant |
1.5% |
|
| Interstitial Lung Disease |
11.9% |
| White Blood Cell Count Decreased |
10.5% |
| Pyrexia |
9.7% |
| Thrombocytopenia |
7.3% |
| Septic Shock |
5.2% |
| Acute Myeloid Leukaemia |
5.0% |
| Febrile Neutropenia |
4.8% |
| Vomiting |
4.6% |
| Neutropenia |
4.4% |
| Stomatitis |
4.4% |
| Pneumonia |
4.2% |
| Sepsis |
3.6% |
| Pancytopenia |
3.2% |
| Rash |
3.2% |
| Toxic Skin Eruption |
3.2% |
| Hepatitis B |
3.0% |
| Neutrophil Count Decreased |
3.0% |
| Febrile Bone Marrow Aplasia |
2.8% |
| Polyneuropathy |
2.8% |
| Respiratory Failure |
2.8% |
|
| Concomitant |
| Breast Cancer |
15.1% |
| Product Used For Unknown Indication |
12.7% |
| Drug Use For Unknown Indication |
10.4% |
| Neoplasm Malignant |
7.7% |
| Metastases To Bone |
7.4% |
| Prophylaxis |
6.5% |
| Lymphoma |
5.4% |
| Dermatomyositis |
4.7% |
| Non-hodgkin's Lymphoma |
4.6% |
| Acute Lymphocytic Leukaemia |
3.6% |
| Chemotherapy |
3.0% |
| B-cell Lymphoma |
2.5% |
| Premedication |
2.4% |
| Stem Cell Transplant |
2.4% |
| Multiple Myeloma |
2.3% |
| Rheumatoid Arthritis |
2.1% |
| Infection Prophylaxis |
2.0% |
| Prophylaxis Of Nausea And Vomiting |
1.8% |
| Chronic Lymphocytic Leukaemia |
1.8% |
| Hypertension |
1.7% |
|
| Vomiting |
12.9% |
| White Blood Cell Count Decreased |
12.1% |
| Interstitial Lung Disease |
11.1% |
| Tooth Extraction |
7.8% |
| Thrombocytopenia |
5.1% |
| Osteonecrosis |
4.9% |
| Pyrexia |
4.9% |
| Sepsis |
4.6% |
| Injection Site Phlebitis |
3.5% |
| Myalgia |
3.5% |
| Pancytopenia |
3.5% |
| Weight Decreased |
3.5% |
| Tuberculosis |
3.2% |
| Urticaria |
3.2% |
| Hepatic Function Abnormal |
3.0% |
| Tumour Marker Increased |
3.0% |
| Death |
2.7% |
| Pneumocystis Jiroveci Pneumonia |
2.7% |
| Pancreatitis Acute |
2.4% |
| Renal Disorder |
2.4% |
|
| Interacting |
| Product Used For Unknown Indication |
38.6% |
| Hypertension |
18.2% |
| Glomerulonephritis |
10.2% |
| Erysipelas |
3.4% |
| Hyperlipidaemia |
3.4% |
| Metabolic Acidosis |
3.4% |
| Non-hodgkin's Lymphoma |
3.4% |
| Oedema Peripheral |
3.4% |
| Plasma Cell Myeloma |
3.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.4% |
| Renal Impairment |
3.4% |
| Constipation |
1.1% |
| Dyslipidaemia |
1.1% |
| Gout |
1.1% |
| Insomnia |
1.1% |
| Productive Cough |
1.1% |
|
| Drug Interaction |
20.0% |
| Enterocolitis Infectious |
20.0% |
| Surgery |
20.0% |
| Lung Infection |
10.0% |
| Platelet Count Decreased |
10.0% |
| Pneumonia |
10.0% |
| Squamous Cell Carcinoma Of The Tongue |
10.0% |
|
